AuthorMouseDoctor

Antigenic key to MS?…….Again

Recently at ECTRIMS we heard of a plan for antigen-specific tolerance against 12 peptides against MBP. MOG, PLP, RASPGPR2 and GDP-L-fucose synthase to treat MS, starting in Spring 2022 (R Martin ECTRIMS2021). Where did the latter two targets come from? The answer in what we call a “fishing trip” to find targets these two were pulled out Eurpoean patent EP3586866A1 As you know I have...

#MSCOVID19 and anti CD20 and covid-19 vaccination responses. More of the same. T cell responses not affected, so what does this say about how anti-CD20 works in MS?

More of the same….anti-CD20 inhibits seroconversion, but there is a T cell response. Even if there is an antibody response it is of lower quality. Get vaccinated before anti-CD20 and the vaccine response is like controls. Time matters and the longer the interval between dose and vaccine more response. So I think it is safe to say we know this already….but prepared this has not...

The King has not left the Building and is Back Again within a Week..Antibody responses on anti-CD20 and delays

Dr. Marton König (i.e. King in Norwegian) appeared on the blog earlier this week and is back again, to further show you what I have been saying for months. “If you want to optimise your antibody response on ocrelizumab you need to consider a delay”. This study is from the next-door neighbour of rituxiland and shows that if you are on rituximab it is perhaps worth considering a delay...

T time …..Another way that influences of T cells inhibit MS?..or is it T blinker time?

CD40 is a costimulatory protein (needed for activation of cells in addition to signalling via the antigen receptor) found on antigen-presenting cells including B cells, macrophages and dendritic cells. EBV induces B cell activation as it produces molecules that mimics the activation of B cell receptor (meaning that the B cell doesnt need to see its target for activation) and mimics the...

#MSCOVID19 Third Dose Boostsers. A little, I mean only a little better for ani-CD20 but not for fingolimod.

Apologises for interupting NDG day, but I think it is important news. I know you are all bored with COVID-19 but you have choices to make and therefore you need data. Here is some third dose-booster data (100 using rituximab, 1 ocrelizumab, and 29 fingolimod) and as I have predicted it is not good reading. Although some people who did not make a response after 2 doses made a response after 3, the...

#MSCOVID19 vaccines 6 months on

This the follow-up from Israel on the Vaccine study looking at 6 month follow-up ocrelizumab and fingolimod never got going maybe there is a drop with other DMT around 6 months and supports the view that boosters should be taken to boost protective antibody levels. Achiron A, Mandel M, Dreyer-Alster S, Harari G, Dolev M, Menascu S, Magalashvili D, Flechter S, Givon U, Guber D, Sonis P, Zilkha...

ECTRIMS2021. The CD20-gurus says that ocrelizumab/rituximab works because of an effect on CD20 T cells…It’s T time

If you talk about B cells in MS there are two names that pop-up over and over again. Guru I from the West-side and Guru II from the East-side. No this is not me in the East End of London. Members for Guru II’s lab have been asking “How does ocrelizumab inhibit MS?”…….My simplistic easy view is that ocrelizumab depletes pathogenic B cells. However it seems that it is...

B cell depletion with ofatumumab and a new-kid-on the (CD20) block with the appearence of “Ubli” at ECTRIMS2021

Ofatumumab antibody depletes B cells. Sure it is going to deplete them T cells too . It depletes B cells, so no surprise there (see below). It is given every month to wipe away the B cells in the blood. What does it do to memory B cells? I have no idea but would say that it is likely. What does it do to CD20 T cells…I probably would answer “I don’t care” but if the Guru of...

HSCT Chicago style

I dont need to say anything here. HSCT chicago style is not where the HSCT replaces the immune system it is there to stop infection as the existing immune system recovers. Therefore it is immunosuppression plus. As you can see the results for relapsing MS is pretty impressive. The study to do a head-head trial has started with the first people enrolled in Sheffield in a trial called MS-STAR. This...

MSCOVID19 The beta interferon experience

As you may realise I don’t report to much on CRAB drugs, because I am not a big fan. Sure they are useful for some people but for many they do not work well enough. We all know this because pharma do trials against them these days, There they know their new-kid-on-the-block drug will do better. You know my opinions about this. However there is some good news in relation to COVID-19...

Translate

Categories

Recent Posts

Recent Comments

Archives